Revenue during the quarter grew 6.28 percent to $382.30 million from $359.70 million in the previous year period. Gross margin for the quarter contracted 97 basis points over the previous year period to 32.28 percent. Total expenses were 85.80 percent of quarterly revenues, down from 87.43 percent for the same period last year. This has led to an improvement of 164 basis points in operating margin to 14.20 percent.

Operating income for the quarter was $54.30 million, compared with $45.20 million in the previous year period.

However, the adjusted operating income for the quarter stood at $54.90 million compared to $46.60 million in the prior year period. At the same time, adjusted operating margin improved 141 basis points in the quarter to 14.36 percent from 12.96 percent in the last year period.

“We delivered a strong performance throughout 2016 with over 9% organic sales growth for the full year and expansion in both gross and operating margins,” said Eric M. Green, president and chief executive officer. “We successfully realigned our Commercial, Global Operations and Innovation & Technology teams to heighten our market-led focus on being the leader in containment, administration and delivery of injectable medicines.

West Pharmaceutical Services expects revenue to be in the range of $1,585 million to $1,610 million for financial year 2017. For financial year 2017, the company projects diluted earnings per share to be in the range of $2.45 to $2.57 on adjusted basis.